KALV
KalVista Pharmaceuticals, Inc.
$27.00
0.00%
No data for this timeframe.
Vol
Analyst ConsensusBuy (54%)
Inst. Holders50 funds
Inst. Value$443.2M
Inst. Activity13 buys / 3 sells
Insider Activity0B / 14S
Insider Net $-$1.9M
SEC Reports10
Recent Activity
Jun 11, 2026
SEC
Chiesi Farmaceutici S.p.A. completed its acquisition of KalVista Pharmaceuticals for $27.00 per share in cash through a
8-K — Impact 5/10
Jun 11, 2026
SEC
An institutional cluster for KalVista Pharmaceuticals shows 4 passive buyers (Wells Fargo, Schwab, Morgan Stanley, UBS)
INST-CLUSTER — Impact 2/10
Jun 11, 2026
Insider
Piekos Brian disposed of 21,661 shares
Chief Financial Officer
Jun 11, 2026
Insider
Palleiko Benjamin L disposed of 479,989 shares
CHIEF EXECUTIVE OFFICER
Jun 11, 2026
Insider
Yea Christopher disposed of 229,918 shares
CHIEF DEVELOPMENT OFFICER
May 26, 2026
SEC
Three C-suite insiders at KalVista (CEO, CMO, CDO) sold a combined $87K in open-market sales on May 18, 2026, at $26.76/
CLUSTER — Impact 5/10
Inst.
Freestone Grove Partners LP — ADD
882,906 shares ($17.8M)
Inst.
DRIEHAUS CAPITAL MANAGEMENT LLC — NEW
564,039 shares ($11.4M)
Price Targets
$27.00
+0.0% upside
Hold
Current $27.00
Low $27.00
Median $27.00
High $27.00
3 analysts
$27.00
$27.00
Analyst Ratings
2Strong Buy
5Buy
6Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 1, 2026 | HC Wainwright & Co. | DOWNGRADE | Buy → Neutral |
| Apr 30, 2026 | Needham | DOWNGRADE | Buy → Hold |
| Mar 26, 2026 | Stifel | MAINTAIN | Buy → Buy |
| Mar 26, 2026 | Citizens | MAINTAIN | Market Outperform → Market Outperform |
| Mar 25, 2026 | Needham | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.29 ▼ -10.3% | $-0.43 — $-0.02 | 6 | |
| Next Q | $-0.27 ▼ -16.1% | $-0.92 — $0.25 | 70% YoY | 6 |
| Current FY | $-0.88 ▼ -9.2% | $-1.70 — $0.59 | 57% YoY | 5 |
| Next FY | $1.54 ▲ +28.7% | $0.44 — $3.81 | 276% YoY | 4 |
Latest Reports
NEUTRAL
8-K
5/10
Chiesi Farmaceutici S.p.A. completed its acquisition of KalVista Pharmaceuticals for $27.00 per share in cash through a
Jun 11, 2026
NEUTRAL
INST-CLUSTER
2/10
An institutional cluster for KalVista Pharmaceuticals shows 4 passive buyers (Wells Fargo, Schwab, Morgan Stanley, UBS)
Jun 11, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $76.4M | — |
| Capital World Investors | $56.5M | — |
| Point72 Asset Management, L.P. | $43.0M | NEW |
| STATE STREET CORP | $39.4M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $36.8M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 11, 2026 | Piekos Brian | D | $0.00 |
| Jun 11, 2026 | Palleiko Benjamin | D | $0.00 |
| Jun 11, 2026 | Yea Christopher | D | $0.00 |
| Jun 11, 2026 | Yea Christopher | D | $0.00 |
| Jun 11, 2026 | Yea Christopher | D | $0.00 |
50 institutional holders with $443.2M total value (22,026,410 shares) as of 2026-Q1. Top holders: BlackRock,, Capital, Point72. Net buying activity: 13 institutions added/increased vs 3 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 3,795,897 | $76.4M | 17.2% | — |
| 2 | Capital World Investors | 2,808,583 | $56.5M | 12.8% | — |
| 3 | Point72 Asset Management, L.P. | 2,136,940 | $43.0M | 9.7% | NEW |
| 4 | STATE STREET CORP | 1,955,844 | $39.4M | 8.9% | — |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 1,830,467 | $36.8M | 8.3% | — |
| 6 | Woodline Partners LP | 1,509,920 | $30.4M | 6.9% | — |
| 7 | Freestone Grove Partners LP | 882,906 | $17.8M | 4.0% | ADD +39.5% |
| 8 | GOLDMAN SACHS GROUP INC | 824,293 | $16.6M | 3.7% | — |
| 9 | DRIEHAUS CAPITAL MANAGEMENT LLC | 564,039 | $11.4M | 2.6% | NEW |
| 10 | BANK OF AMERICA CORP /DE/ | 555,628 | $11.2M | 2.5% | ADD +42.5% |
| 11 | BARCLAYS PLC | 537,061 | $10.8M | 2.4% | DOUBLED +242.1% |
| 12 | SCHRODER INVESTMENT MANAGEMENT GROUP | 506,743 | $9.3M | 2.1% | TRIM -56.8% |
| 13 | MORGAN STANLEY | 439,099 | $8.8M | 2.0% | TRIM -37.3% |
| 14 | VANGUARD PORTFOLIO MANAGEMENT LLC | 362,900 | $7.3M | 1.6% | — |
| 15 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 323,451 | $6.5M | 1.5% | DOUBLED +183.7% |
| 16 | VANGUARD FIDUCIARY TRUST CO | 276,391 | $5.6M | 1.3% | — |
| 17 | CITIGROUP INC | 244,261 | $4.9M | 1.1% | — |
| 18 | AMERIPRISE FINANCIAL INC | 229,984 | $4.6M | 1.0% | DOUBLED +558.4% |
| 19 | FMR LLC | 187,848 | $3.8M | 0.9% | ADD +68.0% |
| 20 | ExodusPoint Capital Management, LP | 177,274 | $3.6M | 0.8% | DOUBLED +783.7% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Freestone Grove Partners LP | ADD | 633,019 | 882,906 | +39.5% | $17.8M | 2026-Q1 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | NEW | — | 564,039 | — | $11.4M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | ADD | 389,813 | 555,628 | +42.5% | $11.2M | 2026-Q1 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | TRIM | 1,171,755 | 506,743 | -56.8% | $9.3M | 2026-Q1 |
| MORGAN STANLEY | TRIM | 700,228 | 439,099 | -37.3% | $8.8M | 2026-Q1 |
| AMERIPRISE FINANCIAL INC | DOUBLED | 34,929 | 229,984 | +558.4% | $4.6M | 2026-Q1 |
| FMR LLC | ADD | 111,807 | 187,848 | +68.0% | $3.8M | 2026-Q1 |
| ExodusPoint Capital Management, LP | DOUBLED | 20,061 | 177,274 | +783.7% | $3.6M | 2026-Q1 |
| Brevan Howard Capital Management LP | DOUBLED | 59,147 | 125,049 | +111.4% | $2.4M | 2026-Q1 |
| PANAGORA ASSET MANAGEMENT INC | TRIM | 109,391 | 50,792 | -53.6% | $1.0M | 2026-Q1 |
| FEDERATED HERMES, INC. | DOUBLED | 75 | 3,719 | +4858.7% | $74.9K | 2026-Q1 |
| BNP Paribas Asset Management Holding S.A. | ADD | 613 | 952 | +55.3% | $19.2K | 2026-Q1 |
| CWM, LLC | ADD | 659 | 901 | +36.7% | $18.1K | 2026-Q1 |
| Rockefeller Capital Management L.P. | DOUBLED | 133 | 665 | +400.0% | $13.4K | 2026-Q1 |
| Allworth Financial LP | DOUBLED | 263 | 573 | +117.9% | $11.5K | 2026-Q1 |
| PRICE T ROWE ASSOCIATES INC /MD/ | ADD | 23,118 | 29,367 | +27.0% | $592.00 | 2026-Q1 |
| Point72 Asset Management, L.P. | NEW | — | 2,283,766 | — | $36.9M | 2025-Q4 |
| PANAGORA ASSET MANAGEMENT INC | TRIM | 197,335 | 109,391 | -44.6% | $1.8M | 2025-Q4 |
| Nuveen, LLC | ADD | 79,758 | 107,129 | +34.3% | $1.7M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 37,244 | 56,014 | +50.4% | $904.6K | 2025-Q4 |
| Zurcher Kantonalbank (Zurich Cantonalbank) | DOUBLED | 4,545 | 17,868 | +293.1% | $288.6K | 2025-Q4 |
| STATE OF WISCONSIN INVESTMENT BOARD | NEAR_EXIT | 65,960 | 15,923 | -75.9% | $257.2K | 2025-Q4 |
| Rathbones Group PLC | TRIM | 18,422 | 12,272 | -33.4% | $198.2K | 2025-Q4 |
| Magnetar Financial LLC | TRIM | 26,924 | 10,938 | -59.4% | $176.6K | 2025-Q4 |
| Mirae Asset Global Investments Co., Ltd. | ADD | 1,946 | 2,456 | +26.2% | $39.7K | 2025-Q4 |
12 unique insiders with 50 transactions. Net insider value: -$1.9M ($0.00 bought, $1.9M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 11, 2026 | Piekos Brian | Chief Financial Officer | D | 21,661 | — | — |
| Jun 11, 2026 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | D | 479,989 | — | — |
| Jun 11, 2026 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | D | 229,918 | — | — |
| Jun 11, 2026 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | D | 25,000 | — | — |
| Jun 11, 2026 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | D | 53,500 | — | — |
| Jun 11, 2026 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | D | 125,001 | — | — |
| Jun 11, 2026 | Piekos Brian | Chief Financial Officer | D | 100,000 | — | — |
| Jun 11, 2026 | Piekos Brian | Chief Financial Officer | D | 55,000 | — | — |
| Jun 11, 2026 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | D | 47,354 | — | — |
| Jun 11, 2026 | Unkart Edward W | Director | D | 12,000 | — | — |
| Jun 11, 2026 | Arif Bilal | Chief Operations Officer | D | 100,000 | — | — |
| Jun 11, 2026 | Arif Bilal | Chief Operations Officer | D | 49,000 | — | — |
| Jun 11, 2026 | Sweeny Nicole | Chief Commercial Officer | D | 59,291 | — | — |
| Jun 11, 2026 | Treanor Patrick | Director | D | 17,000 | — | — |
| Jun 11, 2026 | Sweeny Nicole | Chief Commercial Officer | D | 100,000 | — | — |
| Jun 11, 2026 | Sweeny Nicole | Chief Commercial Officer | D | 40,000 | — | — |
| Jun 11, 2026 | Sensenig Bethany | Director | D | 45,000 | — | — |
| Jun 11, 2026 | Audhya Paul K. | CHIEF MEDICAL OFFICER | D | 150,260 | — | — |
| Jun 11, 2026 | Audhya Paul K. | CHIEF MEDICAL OFFICER | D | 100,000 | — | — |
| Jun 11, 2026 | Audhya Paul K. | CHIEF MEDICAL OFFICER | D | 40,000 | — | — |
| Jun 11, 2026 | Fairey William | Director | D | 17,000 | — | — |
| Jun 11, 2026 | Pereira Brian JG | Director | D | 14,000 | — | — |
| Jun 11, 2026 | Stuart Nancy | Director | D | 14,000 | — | — |
| May 27, 2026 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | EXERCISE | 33,800 | $7.07 | $239.0K |
| May 27, 2026 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | SELL | 33,800 | $26.78 | $905.2K |
| May 26, 2026 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | SELL | 1,966 | $26.78 | $52.6K |
| May 26, 2026 | Audhya Paul K. | CHIEF MEDICAL OFFICER | SELL | 2,239 | $26.78 | $60.0K |
| May 26, 2026 | Sweeny Nicole | Chief Commercial Officer | SELL | 1,489 | $26.78 | $39.9K |
| May 22, 2026 | Audhya Paul K. | CHIEF MEDICAL OFFICER | EXERCISE | 5,000 | — | — |
| May 22, 2026 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | EXERCISE | 3,125 | — | — |
| May 22, 2026 | Sweeny Nicole | Chief Commercial Officer | EXERCISE | 5,000 | — | — |
| May 22, 2026 | Piekos Brian | Chief Financial Officer | SELL | 1,489 | $26.78 | $39.9K |
| May 22, 2026 | Sweeny Nicole | Chief Commercial Officer | SELL | 1,861 | $26.78 | $49.8K |
| May 22, 2026 | Audhya Paul K. | CHIEF MEDICAL OFFICER | SELL | 2,685 | $26.78 | $71.9K |
| May 22, 2026 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | SELL | 2,358 | $26.78 | $63.2K |
| May 22, 2026 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | SELL | 10,926 | $26.78 | $292.6K |
| May 21, 2026 | Piekos Brian | Chief Financial Officer | EXERCISE | 5,000 | — | — |
| May 21, 2026 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | EXERCISE | 3,750 | — | — |
| May 21, 2026 | Audhya Paul K. | CHIEF MEDICAL OFFICER | EXERCISE | 6,250 | — | — |
| May 21, 2026 | Sweeny Nicole | Chief Commercial Officer | EXERCISE | 6,250 | — | — |
| May 21, 2026 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | EXERCISE | 23,250 | — | — |
| May 18, 2026 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | SELL | 1,129 | $26.76 | $30.2K |
| May 18, 2026 | Audhya Paul K. | CHIEF MEDICAL OFFICER | SELL | 1,032 | $26.76 | $27.6K |
| May 18, 2026 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | SELL | 1,108 | $26.76 | $29.7K |
| May 17, 2026 | Audhya Paul K. | CHIEF MEDICAL OFFICER | EXERCISE | 2,419 | — | — |
| May 17, 2026 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | EXERCISE | 2,419 | — | — |
| May 17, 2026 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | EXERCISE | 1,774 | — | — |
| May 12, 2026 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | SELL | 3,322 | $26.71 | $88.7K |
| May 11, 2026 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | EXERCISE | 7,120 | — | — |
| Apr 17, 2026 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | SELL | 9,550 | $20.22 | $193.1K |
10 SEC filing reports analyzed. Sentiment: 1 bullish, 5 bearish, 0 mixed, 4 neutral. Avg impact: 5.1/10.
NEUTRAL
8-K
5/10
Chiesi Farmaceutici S.p.A. completed its acquisition of KalVista Pharmaceuticals for $27.00 per shar
Jun 11, 2026
NEUTRAL
INST-CLUSTER
2/10
An institutional cluster for KalVista Pharmaceuticals shows 4 passive buyers (Wells Fargo, Schwab, M
Jun 11, 2026
BEARISH
CLUSTER
5/10
Three C-suite insiders at KalVista (CEO, CMO, CDO) sold a combined $87K in open-market sales on May
May 26, 2026
NEUTRAL
CLUSTER
2/10
Two C-suite insiders, the CEO and CMO of KalVista, made nominal open-market sales totaling $58K (-0.
May 19, 2026
BULLISH
8-K
8/10
Chiesi Farmaceutici will acquire KalVista for $27.00 per share in cash, valuing the company at appro
Apr 29, 2026
BEARISH
CLUSTER
6/10
KalVista Pharmaceuticals executives Palleiko (CEO) and Piekos (CFO) sold shares worth $231K in aggre
Apr 20, 2026
BEARISH
CLUSTER
6/10
Seven executives at KalVista Pharmaceuticals, including the CEO, CFO, CMO, CDO, and CCO, exercised s
Feb 25, 2026
BEARISH
CLUSTER, CLUSTER
7/10
Multiple C-suite executives at KalVista Pharmaceuticals (KALV) sold shares in a coordinated cluster
Feb 25, 2026
BEARISH
CLUSTER
6/10
Multiple C-suite executives at KalVista Pharmaceuticals (KALV) sold shares in a concentrated 7-day w
Feb 25, 2026
NEUTRAL
CLUSTER
4/10
Two C-suite executives at KalVista Pharmaceuticals — the CFO and Chief Commercial Officer — sold sha
Feb 25, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Hold (54% buy). Based on 13 analysts: 2 strong buy, 5 buy, 6 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$27.00 mean target
+0.0% upside
Hold (3.00)
$27.00 Low
$27.00 High
| Metric | Value |
|---|---|
| Current Price | $27.00 |
| Target Low | $27.00 |
| Target Mean | $27.00 |
| Target Median | $27.00 |
| Target High | $27.00 |
| # Analysts | 3 |
| Recommendation | Hold (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.29 | $-0.43 | $-0.02 | — | -10.3% | 4↑ 2↓ | $0.0B | — | 6 |
| Next Q 2026-09-30 |
$-0.27 | $-0.92 | $0.25 | 70.3% | -16.1% | 4↑ 1↓ | $0.1B | 0.0% | 6 |
| Current FY 2026-12-31 |
$-0.88 | $-1.70 | $0.59 | 56.8% | -9.2% | 6↑ 1↓ | $0.2B | 334.9% | 5 |
| Next FY 2027-12-31 |
$1.54 | $0.44 | $3.81 | 276.0% | +28.7% | 3↑ 2↓ | $0.3B | 63.2% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.287 | |
| 7d ago | $-0.260 | -0.027 |
| 30d ago | $-0.260 | -0.027 |
| 60d ago | $-0.297 | +0.010 |
| 90d ago | $-0.379 | +0.092 |
4 analyst firms have rated this stock: 0 upgrades, 2 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 1, 2026 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
| Apr 30, 2026 | Needham | DOWNGRADE | Buy | Hold |
| Mar 26, 2026 | Stifel | MAINTAIN | Buy | Buy |
| Mar 26, 2026 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| Mar 25, 2026 | Needham | MAINTAIN | Buy | Buy |
| Jan 9, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 9, 2026 | Needham | MAINTAIN | Buy | Buy |
| Jan 6, 2026 | Needham | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 5 | 6 | 0 | 0 | 54% | |
| May 1, 2026 | 3 | 6 | 4 | 0 | 0 | 69% | |
| Apr 1, 2026 | 6 | 8 | 1 | 0 | 0 | 93% | |
| Mar 1, 2026 | 6 | 8 | 1 | 0 | 0 | 93% | |
| Feb 1, 2026 | 6 | 8 | 1 | 0 | 0 | 93% | |
| Jan 1, 2026 | 6 | 8 | 1 | 0 | 0 | 93% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 9, 2026
Clinical Trial
PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial
Phase Phase 3 — COMPLETED
Jun 8, 2026
clinical_trial_readout
Results Pending: KVD900 600 mg (Phase 3) — Completed 12d ago
Trial: PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial
Sponsor: KalVista Pharmaceuticals, Ltd.
Phase: P
Jun 5, 2026
Clinical Trial
An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
Phase Phase 3 — COMPLETED
Jun 5, 2026
clinical_trial_readout
Results Pending: KVD900 600 mg (Phase 3) — Completed 9d ago
Trial: An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adoles
May 27, 2026
short_volume
Short Volume: KALV — 72.0% short (0.5M / 0.8M)
Short: 544,184 | Exempt: 84,637 | TRF Vol: 755,936 | Short Ratio: 72.0% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: KALV — 55.7% short (0.3M / 0.6M)
Short: 313,980 | Exempt: 945 | TRF Vol: 563,604 | Short Ratio: 55.7% | Off-exchange volume (dark pool + OTC)
May 13, 2026
short_interest
FTD: KALV — 21,201 shares ($0.6M) failed to deliver
Settlement: 20260513, Price: $26.73, FTD Value: $566,702.73, KALVISTA PHARMACEUTICALS INC C
May 6, 2026
Clinical Trial
A Trial to Evaluate the Efficacy and Safety of Different Doses of KVD824 for Prophylactic Treatment of HAE Type I or II
Phase Phase 2 — TERMINATED
May 6, 2026
short_interest
FTD: KALV — 27,035 shares ($0.7M) failed to deliver
Settlement: 20260506, Price: $26.71, FTD Value: $722,104.85, KALVISTA PHARMACEUTICALS INC C
Apr 30, 2026
short_interest
FTD: KALV — 125,753 shares ($3.4M) failed to deliver
Settlement: 20260430, Price: $26.67, FTD Value: $3,353,832.51, KALVISTA PHARMACEUTICALS INC C
Apr 23, 2026
short_volume
Short Volume: KALV — 88.1% short (1.0M / 1.1M)
Short: 1,013,537 | Exempt: 0 | TRF Vol: 1,149,831 | Short Ratio: 88.1% | Off-exchange volume (dark pool + OTC)
Apr 17, 2026
short_interest
FTD: KALV — 189,118 shares ($3.7M) failed to deliver
Settlement: 20260417, Price: $19.56, FTD Value: $3,699,148.08, KALVISTA PHARMACEUTICALS INC C
Apr 13, 2026
clinical_trial_readout
T-90d Trial Readout: KVD900 600 mg (Phase 3)
Trial: PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial
Sponsor: KalVista Pharmaceuticals, Ltd.
Phase: P
Apr 13, 2026
clinical_trial_readout
T-90d Trial Readout: KVD900 600 mg (Phase 3)
Trial: An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adoles
Apr 7, 2026
short_interest
FTD: KALV — 163,514 shares ($3.3M) failed to deliver
Settlement: 20260407, Price: $20.19, FTD Value: $3,301,347.66, KALVISTA PHARMACEUTICALS INC C
Apr 6, 2026
clinical_trial_readout
T-90d Trial Readout: KVD900 600 mg (Phase 3)
Trial: An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adoles
Apr 6, 2026
clinical_trial_readout
T-90d Trial Readout: KVD900 600 mg (Phase 3)
Trial: PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial
Sponsor: KalVista Pharmaceuticals, Ltd.
Phase: P
Apr 6, 2026
short_interest
FTD: KALV — 184,602 shares ($3.7M) failed to deliver
Settlement: 20260406, Price: $19.90, FTD Value: $3,673,579.8, KALVISTA PHARMACEUTICALS INC C
Apr 1, 2026
Clinical Trial
Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II
Phase Phase 3 — COMPLETED